Final efficacy analysis shows phase III study of BNT-162b2 meets primary efficacy endpoints Nov. 18, 2020
Arcturus reports interim data from phase I/II study of COVID-19 vaccine candidate ARCT-021 Nov. 10, 2020
RSS